Work

PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo

Year: 2022

Type: article

Source: Cancer Letters

DOI: 10.1016/j.canlet.2022.215832

Authors: Yonggang Sha, Jian Wu, Barry Paul, Yue Zhao, Parker Mathews, Zhiguo Li, John Norris, Endi Wang, Donald P. McDonnell, Yubin Kang

Institutions: Duke Medical Center, Duke Cancer Institute, Duke University

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Sanofi, Incyte, Takeda Oncology, Sanofi Genzyme, National Cancer Institute, Duke Cancer Institute

Awards: G3891775111, Effects of PPAR agonists on response to immunomodulatory agents in patients with multiple myeloma, Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma

OpenAlex ID: W4286435235

FWCI: 1.557

Cites: 82

Cited by: 11

Related to: 10